XML 16 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 792,973 $ 879,520
Accounts receivable 136  
Prepaid expenses and other current assets 16,739 13,432
Research and development incentives receivable 46,238 35,653
Total current assets 856,086 928,605
Property and equipment, net 8,736 9,516
Operating lease right-of-use assets 6,712 7,673
Other assets 12,360 11,074
Total assets 883,894 956,868
Current liabilities:    
Accounts payable 11,107 15,793
Accrued expenses and other current liabilities 33,992 41,246
Deferred revenue, current portion 12,524 10,191
Total current liabilities 57,623 67,230
Operating lease liabilities, net of current portion 2,609 3,990
Deferred revenue, net of current portion 82,213 91,467
Other long-term liabilities 1,116 1,121
Total liabilities 143,561 163,808
Commitments and contingencies (Note 11)
Shareholders' equity:    
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 158,505,729 and 155,876,645 shares authorized on March 31, 2025 and December 31, 2024, respectively; 69,202,355 and 69,061,418 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 892 890
Additional paid-in capital 1,482,447 1,472,842
Accumulated other comprehensive (loss) income (1,461) 119
Accumulated deficit (741,545) (680,791)
Total shareholders' equity 740,333 793,060
Total liabilities and shareholders' equity $ 883,894 $ 956,868